Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Promius Pharma, LLC

ClinicalTrials.gov Identifier:

NCT00828412

First received: January 21, 2009

Last updated: October 14, 2013

Last verified: October 2013

History of Changes

Results First Received: September 17, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Single Blind (Investigator); Primary Purpose: Treatment
Condition:	Atopic Dermatitis
Interventions:	Device: EpiCeram Skin Barrier Emulsion Drug: Desonide Cream 0.05%

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
EpiCeram Skin Barrier Emulsion	EpiCeram Skin Barrier Emulsion
Desonide Cream 0.05%	Desonide Cream 0.05%

Participant Flow: Overall Study

	EpiCeram Skin Barrier Emulsion	Desonide Cream 0.05%
STARTED	50	50
COMPLETED	41	48
NOT COMPLETED	9	2

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
EpiCeram Skin Barrier Emulsion	EpiCeram Skin Barrier Emulsion
Desonide Cream 0.05%	Desonide Cream 0.05%
Total	Total of all reporting groups

Baseline Measures

	EpiCeram Skin Barrier Emulsion	Desonide Cream 0.05%	Total
Number of Participants [units: participants]	50	50	100
Age [units: participants]
<=18 years	50	50	100
Between 18 and 65 years	0	0	0
>=65 years	0	0	0
Age [units: years] Mean ± Standard Deviation	5.5 ± 3.5	4.8 ± 3.3	5.2 ± 3.4
Gender [units: participants]
Female	25	30	55
Male	25	20	45
Region of Enrollment [units: participants]
United States	50	50	100
Three item severity score ^[1] [units: scale] Mean ± Standard Deviation	5.5 ± 0.7	5.5 ± 0.7	5.5 ± 0.7

[1]	The average of the sum of scores for erythema, edema/papulation, and excoriation for two target lesions. Scoring on a scale of 0 to 3 (none to severe). Maximum score is 9.

Outcome Measures

1. Primary:

Change From Baseline in Three Item Severity Score [ Time Frame: 6 weeks ]

Show Outcome Measure 1

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Joanne Fraser
Organization: Promius Pharma
phone: 908 429-4504
e-mail: joannefraser@promiuspharma.com

No publications provided

Responsible Party:	Promius Pharma, LLC
ClinicalTrials.gov Identifier:	NCT00828412 History of Changes
Other Study ID Numbers:	EPC0801
Study First Received:	January 21, 2009
Results First Received:	September 17, 2013
Last Updated:	October 14, 2013
Health Authority:	United States: Institutional Review Board

To Top